TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Clinical Study Comparing Two Closure Techniques of Excised Keloids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or females, in good health, and at least 12 years of age.~* Individuals with 2 or more keloids on the trunk, arm, leg, and neck between 0.5 and 2 cm in length.~* Individuals who are willing and able to participate in the requirements of the study, including signing the informed consent.~* In the opinion of the investigator, the 2 keloids can be excised in a similar manner and closed properly with the two techniques and will benefit from the procedure.~* In the opinion of the investigator, the keloid could benefit from surgical procedure.~Exclusion Criteria:~* Individuals with keloids that do not fit into the criteria.~* Individuals who are planning pregnancy, pregnant, or breast feeding.~* Individuals with a history of medical or dermatologic conditions which, in the opinion of the investigator, would put the subject at heightened risk or would limit complicate the study evaluations required by the protocol.~* Individuals who present with excessive body hair in the designed keloid area.~* Individuals with uncontrolled diabetes.~* Individuals with autoimmune disorders (HIV/AIDs, SLE).~* Subjects who have received keloid treatment within one month of the first day of the study.~* Individuals who plan to receive keloid treatment(s) during the study.~* Individuals who are currently taking prescription or over the counter medication or interventions on a regular basis that as part of their mechanism of action, have the potential to mask an inflammatory reaction. Examples of such medications include, but are not limited to, corticosteroids, non-steroid anti-inflammatory drugs (NSAIDs), antihistamines, aspirin (81mg or less daily dosage permissible), or other medications that in the opinion of the investigator or designee may expose the subject to heightened risk or complicate the study assessments.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Suture (Type: ACTIVE_COMPARATOR): A keloid will be surgically excised and the surgical wound generated will be randomized to be closed with sutures.
- Clozex (Type: ACTIVE_COMPARATOR): One keloid will be surgically excised and the surgical wound generated will be randomized to be closed with Clozex.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Fast Infrared Meibography (Photography)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria~Patients attending the CPU will be offered the opportunity to take part if they comply with the following:~* Over 18 years of age~* Able to give their informed consent~Exclusion criteria:~* Patients under the age of 18 years of age~* Poor understanding of language~* Ocular allergies~* History of contact lens wear~* History of eye or eyelid surgery~* Systemic or ocular diseases that may interfere with tear film production or function.~* Use of systemic medication with tetracycline derivatives, antihistamines, isotretinoin, or nutritional supplements for MGD.~* Use of topical ciclosporin-A or steroids beginning within the last month.~* Refusal for patient's own GP to be informed of participation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- No arms (Type: OTHER): No randomisation therefore no arms. All patients will receive the same research treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Hypofractionated Radiotherapy Alone in Locally Advanced Nonsmall Cell Lung Cancer Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histological confirmation of non-small cell lung cancer by either biopsy or cytology~* American Joint Committee on Cancer (AJCC) 8th Edition Stage II-III or ultracentral Stage IB disease as determined by PET/CT and MRI Brain~* Ultracentral disease will be defined as edge of gross visible tumor within 1.0 cm of the proximal bronchial tree.~* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-3~* Participant is not eligible for or has declined surgical resection or stereotactic body radiotherapy as determined by the treating physician~* Participant is not eligible for or has declined concurrent chemotherapy as determined by the treating physician~* While investigators expect it to be an uncommon event, sequential use of systemic therapy after completion of radiation therapy is permissible if the participant's status improves such that they become eligible for such therapies, per the discretion of a multidisciplinary tumor board.~* Negative serum or urine pregnancy test within 2 weeks of the date of enrollment for women of child-bearing potential.~* Ability to understand and the willingness to sign an IRB-approved informed consent document (either directly or via a legally authorized representative).~Exclusion Criteria:~* History of previous thoracic radiotherapy with the exception of prior radiotherapy for breast cancer without overlap of the fields with the cancer to be treated.~* Prior systemic therapy or surgery for the study cancer.~* Prior malignancy within the past two years except for non-melanoma skin cancer, prostate cancer, or any in-situ malignancy.~* Receipt of anti-angiogenic therapy, such as bevacizumab, within 6 months of enrollment.~* Pregnant women are excluded from this study because radiation therapy has known potential for teratogenic or abortifacient effects.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hypofractionated Radiation Therapy (Type: EXPERIMENTAL): Hypofractionated radiation therapy will be delivered to all participants. The radiation will be planned in a special way to give the biggest parts of the tumors that are the most difficult to control a little more radiation every day than the lower risk areas.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Recormon (Epoetin Beta) in Anemic Patients With Non-Myeloid Malignancy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients with a non-myeloid malignancy~* Anemia~Exclusion Criteria:~* Transfusion of red blood cells within 2 months of study drug~* Treatment-resistant hypertension~* Acute or chronic bleeding (requiring therapy) within 3 months of study drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Epoetin Beta 30000 IU (Type: EXPERIMENTAL): Dosage at Initiation: Subcutaneous injection of 30000 IU epoetin beta administered once a week. Dosage could be increased to 30000 IU twice a week or 60000 IU once a week after 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trial About Hepatic Security of Antiretroviral Treatment Based on Kaletra Versus Nevirapine in Co-infected HIV/HCV Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 years old or elder.~2. HCV and HIV co-infected patients.~3. Patients with antiretroviral treatment based in NVP plus 2 NRTIs (or 1 NRTI and Tenofovir), with undetectable viral load (under 50 copies/mL) during at least the last 24 weeks.~4. If women and of childbearing age, negative pregnancy test. Furthermore, barrier contraceptive method must be undertaken during the study.~5. Date and signature of the informed consent.~Exclusion Criteria:~1. Concomitant treatment with drugs that can significantly interact with the study drugs.~2. Opportunistic infections in the last 6 months.~3. Patients who can be candidates for an HCV infection treatment in the next 3 years.~4. Patients in who efficacy of previous NRTIs can not be ensured. For example, patients with mono or dual therapy history or with previous blips in whom NRTI-related mutations were identified that could reduce the sensibility to the used backbone.~5. Active alcohol consumption (over 50 g per day) or other substance abuse.~6. Pregnant or breastfeeding women.~7. Patients with transaminase level over 5 times the Upper Limit of Normality (ULN) or Creatinin over 2 mg/dL or Total Bilirubin over 3 times the ULN.~8. Any formal contraindication for being treated with the study drugs.~9. Patients who, basing in their antiretroviral treatment history, could be considered as being infected with a virus that has no sensibility to LPV.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Nevirapine
- 2 (Type: EXPERIMENTAL): Lopinavir/ritonavir

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Incidence of Oral Candidiasis, Prevalence of C. Dubliniensis in HIV Patients and In-vitro Azole Susceptibility

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Any patient 18 years old or older with a documented diagnosis of HIV infection with or without AIDS-defining illnesses at the time of assessment, who is presenting with clinical symptoms and physical findings compatible with oropharyngeal candidiasis (as defined by the IDSA Guidelines for the Treatment and Management of HIV and HIV- related complications.~Exclusion Criteria:~* Any prior diagnosis or established treatment for oropharyngeal, mucocutaneous or esophageal candidiasis documented in the patient's chart or any proven diagnosis based on reviews of physically available medical records and or history provided by patients that can be subject to later confirmation pertaining to the use of parenteral antifungals within 6 months prior to enrollment (azoles, echinocandins, amphotericin B, Flucytosine, etc).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Positron Emission Tomography and Computed Tomography in Planning Treatment for Patients Undergoing 3-Dimensional Conformal Radiation Therapy for Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery. ICORG 06-35

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven (biopsy or cytology) NSCLC (SCC, Adenocarcinoma, Large Cell)~* TNM clinical non-operable stage I/II and non-resectable stage IIIa/b without pleural effusion~* Measurable disease~* No other malignancy, except non-melanomatous skin cancer, within 5 years prior to participation in this study; the disease-free interval from any prior carcinoma must be continuous~* Patient suitable for radical 3-DCRT~* ECOG-Performance status ≤ 2 / KPS \> or equal to 60~* Weight loss \<10% within the 3 months prior to diagnosis~* No prior radiotherapy to the thorax~* Patient is suitable for lung-board immobilisation~* No chemotherapy received prior to planning PET-CT scan~* Age 18 and over~* Provision of written informed consent~Exclusion Criteria:~* Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the trial or if it is felt by the research / medical team that the patient may not be able to comply with the protocol.~* FEV1 \< 1

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 3-DCRT (Type: EXPERIMENTAL): Patients will receive a total dose of 60-66 Gy in 30-33 fractions with 3-DCRT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Jumping Exercises Approach in Individuals With Chronic Ankle Instability

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ankle injury more than 6 months ago~* Chronic instability~* Functional instability of the ankle~* Experience with proprioceptive exercises~Exclusion Criteria:~* Foot surgery~* Fresh ankle injury~* Acute foot pain with signs of inflammation~* Mechanical / anatomical ankle instability~* Athletes with regularly jumping exercise (eg volleyball, basketball)~* Taking medications which affect balance and coordination~* Diseases that affect the balance~* Serious diseases such as tumors, infections, neuropathies, severe articular degeneration~* Non-German-speaking patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Jumping exercise (Type: EXPERIMENTAL): Physical therapy with a focus on specific jumping exercise. The jumping exercise will be performed for 12 weeks (3x/week), with a break of day between workouts. The 40-minute workout is completed 2 times under supervision in the clinic's internal training group for outpatients. 1 time they train on their own at home, based on a defined training program. The training process is documented by the training protocol.~The incipient exercise intensity is taking personal performance into account. The exercise intensity is increased by a progressive scheme.
- Strength exercise (Type: ACTIVE_COMPARATOR): Physical Therapy with a focus on stability and strength exercise. Strength exercise arm has also same duration of 12 weeks with comparable intensity. The program is according to a predetermined program. The 60-minute training is completed twice under supervision in the clinic's internal training group for outpatients.There is no contact with participants of other group.~Between the two exercise sessions there is a training free day. The training process is documented by the training protocol. The incipient exercise intensity is considering personal performance. The intensity is increased after workout usual principles. The exercises are described with clear image and load parameters. The training exercises are regularly monitored.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Stage III unresectable or American Joint Committee on Cancer (AJCC) stage IV cutaneous, mucosal, ocular, or unknown primary melanoma with measurable disease by physical examination or imaging studies.~* Palpable cutaneous or nodal metastases suitable for punch, trucut, or similar biopsy if the patient agrees.~* Normal electrocardiogram (EKG)~* Left ventricular ejection fraction (LVEF) \> 40% by Multi Gated Acquisition Scan (MUGA)~* Corrected QT (QTc) \< 500 msec~* Age greater than or equal to 18~* Negative pregnancy test~* Fertile patients must use effective contraception~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2~* Normal organ and marrow function~* Patients on hydrochorthiazide should be switched to a potassium-sparing diuretic or another antihypertensive~* At least 4 weeks since prior radiotherapy~* Patients with cardiac hypertrophy may be enrolled but should be carefully monitored.~Exclusion Criteria:~* Prior FR901228 (depsipeptide)~* Prior chemotherapy~* Other concurrent chemotherapy~* Active central nervous system (CNS) metastases by brain computed tomography (CT) scan or magnetic resonance imaging (MRI)~* History of coronary atherosclerotic heart disease~* History of myocardial infarction~* History of congestive heart failure~* Non-melanoma malignancy within the past 5 years except carcinoma in situ or squamous cell or basal cell skin cancer~* Pregnant or nursing women~* Conditions that in the opinion of the investigator would interfere with the ability of the patient to complete this protocol~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to Depsipeptide~* Co-medication with an agent that causes QTc prolongation~* Human immunodeficiency virus (HIV) positive patients receiving combination anti-retroviral therapy~* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements~* Concurrent radiotherapy~* Left ventricular hypertrophy (LVH) on their baseline EKG tracing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Depsipeptide (Type: EXPERIMENTAL): Depsipeptide is administered as a 4-hour IV infusion weekly in doses of 13 mg/m\^2 for 3 weeks. Repeat cycle every 28 days until unacceptable toxicity or disease progression.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Bioavailability Study of 3 Test Tablet Formulations of Bazedoxifene Compared With A Reference Tablet Formulation of Bazedoxifene/Conjugated Estrogens in Healthy Postmenopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Generally healthy postmenopausal women~* Body mass index (BMI) in the range of 18.0 to 35.0 kg/m2 and body weight \>= 50 kg~Exclusion Criteria:~* Pregnant or nursing females; females of childbearing potential

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Test Treatment 1: bazedoxifene (Type: EXPERIMENTAL): Test Treatment 1
- Test Treatment 2: bazedoxifene (Type: EXPERIMENTAL): Test Treatment 2
- Test Treatment 3: bazedoxifene (Type: EXPERIMENTAL): Test Treatment 3
- Reference Treatment: bazedoxifene/conjugated estrogens (Type: EXPERIMENTAL): Reference Treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: PrEP and Consumptions

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject aged over 18,~* Subject seen in consultation in one of the centers of the study for a renewal of the Prep~* Subject having agreed to participate in the study~Exclusion Criteria:~* Subject not speaking French / illiterate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single Arm (Type: EXPERIMENTAL): To estimate the acceptability and the impact on the management of a systematic identification of the use of psychoactive substances and / or anxio-depressive disorders by self-questionnaire.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: GW823093C For The Treatment Of Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Type 2 diabetes mellitus.~* Managed by diet therapy or receiving treatment with oral anti-diabetic monotherapy (excluding TZD (Thiazolidinediones))~Exclusion criteria:~* Patients who have metabolic disease judged by investigator as a clinically significance~* Serious cardiovascular disease or serious hepatic disease

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- GW823093C A (Type: PLACEBO_COMPARATOR): A=45 mg
- GW823093C B (Type: PLACEBO_COMPARATOR): B=30 mg
- GW823093C C (Type: PLACEBO_COMPARATOR): C=15 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues